priors.science/reviews/atopic-dermatitis-pharmacotherapy

Atopic Dermatitis Pharmacotherapy

The current evidence on 20 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

20claims tracked
293primary papers reviewed
9 Aug 2026latest evidence review
Weeklyre-scored against new papers
9 Established · 8 Likely · 2 Uncertain · 1 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Dupilumab itch reduction in atopic dermatitisDupilumab EfficacyEstablished93%25
Dupilumab EASI-75 in moderate-to-severe atopic dermatitisDupilumab EfficacyEstablished92%23
Upadacitinib EASI-75 in atopic dermatitisJAK Inhibitor EfficacyEstablished92%22
Ruxolitinib cream EASI reduction in atopic dermatitisTopical JAK InhibitorsEstablished90%22
Lebrikizumab EASI-75 in atopic dermatitisIl13 InhibitionEstablished88%28
Nemolizumab pruritus reduction in atopic dermatitisIl31 PathwayEstablished88%24
Dupilumab long-term efficacy over 52 weeksDupilumab EfficacyEstablished86%20
Ruxolitinib cream itch relief versus vehicleTopical JAK InhibitorsEstablished86%19
Abrocitinib rapid itch relief in atopic dermatitisJAK Inhibitor EfficacyEstablished85%20
IL-13 inhibitors quality of life in atopic dermatitisIl13 InhibitionLikely84%20
Dupilumab efficacy with comorbid asthmaDupilumab EfficacyLikely82%24
Upadacitinib versus dupilumab EASI-75Head To Head ComparisonsLikely82%20
Nemolizumab sleep improvement in atopic dermatitisIl31 PathwayLikely82%18
JAK inhibitors dose-dependent efficacy in atopic dermatitisJAK Inhibitor EfficacyLikely78%19
Dupilumab drug survival versus conventional systemicsHead To Head ComparisonsLikely76%17
Tralokinumab IGA clearance in atopic dermatitisIl13 InhibitionLikely75%19
Cyclosporin versus methotrexate in atopic dermatitisConventional SystemicsLong-standingLikely71%12
JAK inhibitor major adverse cardiovascular event risk is age-dependent in atopic dermatitisJAK Inhibitor SafetyUncertain61%19
Methotrexate long-term efficacy in atopic dermatitisConventional SystemicsLong-standingUncertain56%16
JAK inhibitor venous thromboembolism risk in atopic dermatitisJAK Inhibitor SafetyDoubtful35%21
Track Atopic Dermatitis Pharmacotherapy.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.
Where the evidence sits in time
Long-standingMost of this evidence is older than the rest of this field.